

# PRODUCT INFORMATION



## CGI1746

Item No. 18414

CAS Registry No.: 910232-84-7

Formal Name: N-[3-[4,5-dihydro-4-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-5-oxo-2-pyrazinyl]-2-methylphenyl]-4-(1,1-dimethylethyl)-benzamide

MF:  $C_{34}H_{37}N_5O_4$

FW: 579.7


Purity:  $\geq 98\%$

UV/Vis.:  $\lambda_{max}$ : 234, 355 nm

Supplied as: A crystalline solid

Storage:  $-20^{\circ}\text{C}$

Stability:  $\geq 4$  years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

CGI1746 is supplied as a crystalline solid. A stock solution may be made by dissolving the CGI1746 in the solvent of choice, which should be purged with an inert gas. CGI1746 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of CGI1746 in ethanol is approximately 0.25 mg/ml and approximately 25 mg/ml in DMSO and DMF.

CGI1746 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CGI1746 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. CGI1746 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

CGI1746 is a potent, selective inhibitor of Bruton's tyrosine kinase (BTK;  $IC_{50} = 1.9$  nM), a non-receptor tyrosine kinase that is important in B lymphocyte development.<sup>1,2</sup> It blocks both auto- and trans-phosphorylation of BTK by occupying an SH3 binding pocket in the un-phosphorylated enzyme. CGI1746 prevents B-cell antigen receptor-mediated B lymphocyte proliferation and suppresses FC $\gamma$ RIII-induced TNF $\alpha$ , IL-1 $\beta$ , and IL-6 production in macrophages.<sup>1</sup> It reduces cytokine levels within joints and ameliorates symptoms in a mouse model of autoantibody-induced arthritis.<sup>1</sup>

### References

1. di Paolo, J. A., Huang, T., Balazs, M., *et al.* Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. *Nat. Chem. Biol.* **7**(1), 41-50 (2011).
2. Akinleye, A., Chen, Y., Mukhi, N., *et al.* Ibrutinib and novel BTK inhibitors in clinical development. *J. Hematol. Oncol.* **6**:59, (2013).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897  
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM